The previously documented constituents demonstrate multi-target efficacy against VEGF-driven tumor angiogenesis: fucoidan exhibits pan-inhibitory efficacy across diverse malignancies, including multiple myeloma (RPMI-8226, U266) and breast cancer (4T1), which suppresses VEGF expression to potently ameliorate tumor neoangiogenesis (Xue et al., 2012; Liu et al., 2012). The gene discussed is VEGFA; the disease is breast cancer.